Nkarta Inc. (NKTX) News
Filter NKTX News Items
NKTX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
NKTX News Highlights
- NKTX's 30 day story count now stands at 2.
- Over the past 27 days, the trend for NKTX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- CL are the most mentioned tickers in articles about NKTX.
Latest NKTX News From Around the Web
Below are the latest news stories about NKARTA INC that investors may wish to consider to help them evaluate NKTX as an investment opportunity.
Nkarta Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate HighlightsClinical updates on track for NKX101 in first half of 2023 and NKX019 in full year 20232022 year-end cash and cash equivalents of $354.9 millionCash runway anticipated to fund operations into 2025 SOUTH SAN FRANCISCO, Calif., March 16, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today reported financial results for the fourth quarter and year ended December 31, 2022. “Cl |
Nkarta, Inc. (NASDAQ:NKTX) is a favorite amongst institutional investors who own 58%To get a sense of who is truly in control of Nkarta, Inc. ( NASDAQ:NKTX ), it is important to understand the ownership... |
Nkarta to Participate at Upcoming Investor ConferencesSOUTH SAN FRANCISCO, Calif., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at three upcoming investor conferences: SVB Securities Global Biopharma ConferenceFebruary 14, 20233:40 p.m. ET – fireside chat H.C. Wainwright Cell Therapy Virtual ConferenceFebruary 28, 2023Time tbd – fireside chat Cowen 43rd Annual Health Care ConferenceMarch 8, 20232: |
Nkarta Promotes David R. Shook, M.D., to Chief Medical OfficerSOUTH SAN FRANCISCO, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced the promotion of David R. Shook, M.D., to the role of Chief Medical Officer. Dr. Shook has extensive expertise in cell therapy development and continues to lead Nkarta’s global clinical development and regulatory operations. “Dave has been a driving force behind the developm |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayThe biggest pre-market stock movers for Monday include many Chinese shares that traders will want to keep an eye on today! |
Nkarta Announces Updated Clinical Data on Anti-CD19 Allogeneic CAR-NK Cell Therapy NKX019 for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma7 of 10 patients treated with NKX019 monotherapy at 1 billion and 1.5 billion CAR NK cells per dose achieved complete response (70% CR rate)5 CRs achieved across all dose levels after a single cycle (3 weekly doses) of NKX019 monotherapy; 3 partial responses deepened to CR with additional cyclesPatients with CR observed across multiple NHL histologies, including LBCLConsolidation dosing administered to 7 patients with CRs with aim to eradicate residual tumor cells and prolong responseDurable res |
Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX019 NK Cell Therapy ProgramCall scheduled for Monday, December 5, 2022 at 8:00 a.m. ETSOUTH SAN FRANCISCO, Calif., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced that it will host a conference call on Monday, December 5, 2022 at 8:00 a.m. ET to review updated clinical data from the ongoing clinical trial of NKX019, its CD19-directed CAR NK cell therapy candidate. Conference Call and Webcast |
Analysts Are Bullish on These Healthcare Stocks: Wave Life Sciences (WVE), Ayr Wellness (AYRWF)There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Wave Life Sciences (WVE – Research Report), Ayr Wellness (AYRWF – Research Report) and Nkarta (NKTX – Research Report) with bullish sentiments. Wave Life Sciences (WVE) Mizuho Securities analyst Salim Syed maintained a Buy rating on Wave Life Sciences today and set a price target of $13.00. The company's shares closed last Thursday at $4.08. According to TipRanks. |
Nkarta Reports Third Quarter 2022 Financial Results and Corporate HighlightsNKX101 and NKX019 allogeneic cell therapy programs continue to advance following initial clinical data reported in April 2022NKX019 Phase 1 clinical trial recently opened dose expansion cohortsNKX019 clinical update is expected by year-end 2022NKX101 clinical update is expected in first half of 2023Presentations at SITC 2022 on enhanced anti-tumor activity of NKX019 when combined with CD20-targeted monoclonal antibodies in preclinical models, and next-generation commercial-scale NK cell manufact |
Nkarta Presents Data Supporting Engineered NK Cell Based Combination Therapies and Next Generation Commercial-Scale Manufacturing Platform at SITC 37th Annual MeetingImproved Anti-Tumor Activity Demonstrated by the Combination of NKX019 and a CD20-directed Monoclonal Antibody in Preclinical Models Pulsed Stimulation of NK Cells Derived from Peripheral Blood of Healthy Donors Induces Billion-Fold Expansion, Enabling Commercial-Scale Production of NK Cell Therapy from a Selected Single Donor SOUTH SAN FRANCISCO, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell ther |